{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:45:12Z","timestamp":1782783912293,"version":"3.54.5"},"reference-count":89,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Viral vaccine development requires both mechanistic understanding of protective immunity and translational study designs that connect preclinical data with human outcomes. Animal models remain important for early assessment of safety, immunogenicity and protective efficacy, but their predictive value depends on the question being asked, the pathophysiology of infection, the immune mechanisms expected to mediate protection, and the biomarkers chosen to bridge animal and human data. This review focuses on viral vaccines and examines innate and adaptive mechanisms of vaccine-induced protection, including B cell and antibody responses, Fc-mediated functions, Fc glycosylation, T cell memory and CD8+ cytotoxic responses. We discuss common reasons for clinical failure and show how preclinical endpoints can be classified as human-counterpart, surrogate or comparative\/mechanistic readouts. Influenza and COVID-19 examples illustrate how different models can be combined across discovery, challenge, transmission and late-stage bridging studies. Emerging tools such as systems serology, omics, AI\/ML and new approach methods can improve candidate prioritization, but their value depends on assay standardization, biological validation and cautious interpretation. A mechanism-driven model cascade, paired with human-relevant immunological readouts, can improve preclinical interpretation and reduce the risk of advancing candidates that are unlikely to succeed in clinical trials.<\/jats:p>","DOI":"10.3390\/ijms27135790","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:55:11Z","timestamp":1782780911000},"page":"5790","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune Mechanisms and Translational Study Design in Viral Vaccine Development"],"prefix":"10.3390","volume":"27","author":[{"given":"Stephanie","family":"Lim","sequence":"first","affiliation":[{"name":"Artemis Bioservices, Molengraasssingel 10, 2629 JD Delft, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6127-2458","authenticated-orcid":false,"given":"Byron","family":"Martina","sequence":"additional","affiliation":[{"name":"Artemis Bioservices, Molengraasssingel 10, 2629 JD Delft, The Netherlands"},{"name":"School of Medicine, The Avalon University, WTC, Piscaderaweg z\/n, Willemstad, Cura\u00e7ao"},{"name":"Curacao Biomedical & Health Reseach Institute, Pater Euwensweg 36, Willemstad, Cura\u00e7ao"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref_1","unstructured":"WHO (2021). Immunization Agenda 2030: A Global Strategy to Leave no One Behind, World Health Organization."},{"key":"ref_2","unstructured":"Plotkin, S.A., Orenstein, W.A., Offit, P.A., and Edwards, K.M. (2017). Plotkin\u2019s Vaccines, Elsevier. [7th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: An interim analysis of four randomised controlled trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_7","unstructured":"National Academies of Sciences, Engineering, and Medicine (2023). Nonhuman Primate Models in Biomedical Research: State of the Science and Future Needs, The National Academies Press."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/cid\/cit048","article-title":"Complex correlates of protection after vaccination","volume":"56","author":"Plotkin","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Plotkin, S.A., Gilbert, P.B., Nohynek, H., Hombach, J., and O\u2019Brien, K.L. (2023). Recent updates on correlates of vaccine-induced protection. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1081107"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"a031583","DOI":"10.1101\/cshperspect.a031583","article-title":"What is the predictive value of animal models for vaccine efficacy in humans?","volume":"10","author":"Herati","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: The pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41541-024-00872-6","article-title":"Realising the potential of correlates of protection for vaccine development, licensure and use: Short summary","volume":"9","author":"King","year":"2024","journal-title":"npj Vaccines"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kennedy, R.B., Ovsyannikova, I.G., Palese, P., and Poland, G.A. (2020). Current challenges in vaccinology. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01181"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41541-025-01211-z","article-title":"De-risking vaccine development: Lessons, challenges, and prospects","volume":"10","author":"Masignani","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Choy, R.K.M., Bourgeois, A.L., Ockenhouse, C.F., Walker, R.I., Sheets, R.L., and Flores, J. (2022). Controlled human infection models to accelerate vaccine development. Clin. Microbiol. Rev., 35.","DOI":"10.1128\/cmr.00008-21"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/infdis\/jiaf053","article-title":"Controlled human infection studies accelerate vaccine development","volume":"231","author":"Laurens","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref_18","unstructured":"WHO (2025). Key Criteria for the Ethical Acceptability of Controlled Human Infection Studies During a Public Health Emergency, World Health Organization."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-immunol-020711-075032","article-title":"Germinal centers","volume":"30","author":"Victora","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41564-024-01903-7","article-title":"Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans","volume":"10","author":"Kalimuddin","year":"2025","journal-title":"Nat. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Vidarsson, G., Dekkers, G., and Rispens, T. (2014). IgG subclasses and allotypes: From structure to effector functions. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00520"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.13091","article-title":"Correlates of protection against SARS-CoV-2 infection and COVID-19 disease","volume":"310","author":"Goldblatt","year":"2022","journal-title":"Immunol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","article-title":"The role of IgG Fc receptors in antibody-dependent enhancement","volume":"20","author":"Bournazos","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Koch, T., Mellinghoff, S.C., Shamsrizi, P., Addo, M.M., and Dahlke, C. (2021). Correlates of vaccine-induced protection against SARS-CoV-2. Vaccines, 9.","DOI":"10.3390\/vaccines9030238"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gao, R., Sheng, Z., Sreenivasan, C.C., and Wang, D. (2020). Influenza A virus antibodies with antibody-dependent cellular cytotoxicity function. Viruses, 12.","DOI":"10.3390\/v12030276"},{"key":"ref_33","first-page":"965","article-title":"Signal transduction during Fc receptor-mediated phagocytosis","volume":"103","author":"Rosales","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kaplonek, P., Cizmeci, D., Fischinger, S., Collier, A.-R., Suscovich, T., Linde, C., Broge, T., Mann, C., Amanat, F., and Dayal, D. (2022). mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. Sci. Transl. Med., 14.","DOI":"10.1126\/scitranslmed.abm2311"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41590-023-01513-1","article-title":"ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19","volume":"24","author":"Kaplonek","year":"2023","journal-title":"Nat. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"113084","DOI":"10.1016\/j.isci.2025.113084","article-title":"SARS-CoV-2 vaccines elicit differential Fc effector functions","volume":"28","author":"Manamela","year":"2025","journal-title":"iScience"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41564-023-01359-1","article-title":"Fc\u03b3 receptor-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2","volume":"8","author":"Mackin","year":"2023","journal-title":"Nat. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/glycob\/cwaa018","article-title":"Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases","volume":"30","author":"Irvine","year":"2020","journal-title":"Glycobiology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1074\/jbc.M307341200","article-title":"Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies: African trypanosomes as paradigm","volume":"279","author":"Stijlemans","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"14943","DOI":"10.1073\/pnas.0505126102","article-title":"Antibody vs. HIV in a clash of evolutionary titans","volume":"102","author":"Burton","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.str.2007.09.011","article-title":"Structure of an IgNAR-AMA1 complex: Targeting a conserved hydrophobic cleft broadens malarial strain recognition","volume":"15","author":"Henderson","year":"2007","journal-title":"Structure"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Butler, J.E., and Wertz, N. (2012). The porcine antibody repertoire: Variations on the textbook theme. Front. Immunol., 3.","DOI":"10.3389\/fimmu.2012.00153"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Lavinder, J.J., Hoi, K.H., Reddy, S.T., Wine, Y., and Georgiou, G. (2014). Systematic characterization and comparative analysis of the rabbit immunoglobulin repertoire. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101322"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41598-020-57764-7","article-title":"Comparisons of the antibody repertoires of a humanized rodent and humans by high throughput sequencing","volume":"10","author":"Joyce","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wong, J., Tai, C.M., Hurt, A.C., Tan, H.X., Kent, S.J., and Wheatley, A.K. (2020). Sequencing B cell receptors from ferrets (Mustela putorius furo). PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0233794"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4049\/jimmunol.177.2.1129","article-title":"Modulation of the effector functions of a human IgG1 through engineering of its hinge region","volume":"177","author":"Cook","year":"2006","journal-title":"J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41467-024-47928-8","article-title":"The hinge-engineered IgG1-IgG3 hybrid subclass IgGh47 potently enhances Fc-mediated function of anti-streptococcal and SARS-CoV-2 antibodies","volume":"15","author":"Izadi","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-023-00613-1","article-title":"Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design","volume":"8","author":"Loos","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"110174","DOI":"10.1016\/j.isci.2024.110174","article-title":"Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques","volume":"27","author":"Tong","year":"2024","journal-title":"iScience"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc\u03b3RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Golay, J., Andrea, A.E., and Cattaneo, I. (2022). Role of Fc core fucosylation in the effector function of IgG1 antibodies. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.929895"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"107619","DOI":"10.1016\/j.isci.2023.107619","article-title":"Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines","volume":"26","author":"Pongracz","year":"2023","journal-title":"iScience"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Buhre, J.S., Pongracz, T., K\u00fcnsting, I., Lixenfeld, A.S., Wang, W., Nouta, J., Lehrian, S., Schmelter, F., Lunding, H.B., and D\u00fchring, L. (2023). mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1020844"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0167-5699(00)01754-0","article-title":"Natural antibodies and complement link innate and acquired immunity","volume":"21","author":"Ochsenbein","year":"2000","journal-title":"Immunol. Today"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bigay, J., Gorg\u00e9, O., Salcedo, S.P., Chaze, T., Matondo, M., and Gorvel, J.P. (2022). Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.932408"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/ilar.43.4.244","article-title":"Guidelines for the design and statistical analysis of experiments using laboratory animals","volume":"43","author":"Festing","year":"2002","journal-title":"ILAR J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: The valley of death across preclinical and clinical divide\u2014identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl. Med. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: Differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1073\/pnas.1222878110","article-title":"Genomic responses in mouse models poorly mimic human inflammatory diseases","volume":"110","author":"Seok","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M.T., Baker, M., Browne, W.J., Clark, A., Cuthill, I.C., and Dirnagl, U. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol., 18.","DOI":"10.1371\/journal.pbio.3000410"},{"key":"ref_64","unstructured":"ABPI (2025). Use of Animals in Pharmaceutical Research, Association of the British Pharmaceutical Industry."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Crooks, C.M., Chan, C., and Permar, S.R. (2023). Leveraging preclinical study designs to close gaps in vaccine development for perinatal pathogens. J. Exp. Med., 220.","DOI":"10.1084\/jem.20230184"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Chaput, S., Nougair\u00e8de, A., and Touret, F. (2026). In Vitro and In Vivo Models for Drug Development Against Two Hemorrhagic Hareavirales: Rift Valley Fever and Crimean Congo Hemorrhagic Fever Viruses. Viruses, 18.","DOI":"10.3390\/v18030386"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature17655","article-title":"Normalizing the environment recapitulates adult human immune traits in laboratory mice","volume":"532","author":"Beura","year":"2016","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41590-024-01842-9","article-title":"Leveraging dirty mice that have microbial exposure to improve preclinical models of human immune status and disease","volume":"25","author":"Liu","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Sanders, A.E., Arnesen, H., Shepherd, F.K., Putri, D.S., Fiege, J.K., Pierson, M.J., Roach, S.N., Carlsen, H., Masopust, D., and Boysen, P. (2024). Comparison of mouse models of microbial experience reveals differences in microbial diversity and response to vaccination. mSphere, 9.","DOI":"10.1128\/msphere.00654-23"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/v20801530","article-title":"Animal models for influenza virus pathogenesis and transmission","volume":"2","author":"Bouvier","year":"2010","journal-title":"Viruses"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Fukushi, M., Ito, T., Oka, T., Kitazawa, T., Miyoshi-Akiyama, T., Kirikae, T., Yamashita, M., and Kudo, K. (2011). Serial histopathological examination of the lungs of mice infected with influenza A virus. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021207"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1242\/dmm.007823","article-title":"The ferret as a model organism to study influenza A virus infection","volume":"4","author":"Belser","year":"2011","journal-title":"Dis. Model. Mech."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1038\/s41467-020-17367-2","article-title":"SARS-CoV-2 is transmitted via contact and via the air between ferrets","volume":"11","author":"Richard","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"Dowling","year":"2020","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.chom.2020.03.023","article-title":"Infection and rapid transmission of SARS-CoV-2 in ferrets","volume":"27","author":"Kim","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Wei, J., Huang, H., Wu, X., Xu, Y., and Wang, X. (2026). Pathogenesis and Research Models of Acute Influenza-Associated Encephalitis\/Encephalopathy: An Update. Viruses, 18.","DOI":"10.3390\/v18010095"},{"key":"ref_80","first-page":"285","article-title":"Signaling by antibodies: Recent progress","volume":"37","author":"Bournazos","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tim.2011.11.002","article-title":"The pig: A model for human infectious diseases","volume":"20","author":"Meurens","year":"2012","journal-title":"Trends Microbiol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Caffrey, M., Paprotny, I., and Smith, R. (2026). Challenges and progress toward real-time detection of airborne viral pathogens. Crit. Rev. Biotechnol., advance online publication.","DOI":"10.1080\/07388551.2026.2628597"},{"key":"ref_83","unstructured":"Russell, W.M.S., and Burch, R.L. (1959). The Principles of Humane Experimental Technique, Methuen."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14573\/altex.2013.1.003","article-title":"Evidence-based toxicology: The toolbox of validation for the 21st century?","volume":"30","author":"Hartung","year":"2013","journal-title":"ALTEX"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"140701","DOI":"10.1063\/5.0200726","article-title":"Recent advances in 3D printing for in vitro cancer models","volume":"135","author":"Zhang","year":"2024","journal-title":"J. Appl. Phys."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Liu, M., Faris, J.G., Panfil, A.R., and Warren, C.J. (2026). How new approach methods are reshaping virology research. J. Virol., 100.","DOI":"10.1128\/jvi.01326-25"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/1547691X.2022.2088904","article-title":"Immunosafety evaluation in juvenile G\u00f6ttingen minipigs","volume":"19","author":"Allais","year":"2022","journal-title":"J. Immunotoxicol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Zlatina, K., Isernhagen, L., Galuska, C.E., Murani, E., and Galuska, S.P. (2024). Changes in the N-glycosylation of porcine immune globulin G during postnatal development. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1361240"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41541-020-00261-9","article-title":"Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate","volume":"5","author":"Roozendaal","year":"2020","journal-title":"npj Vaccines"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5790\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:02:51Z","timestamp":1782781371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":89,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27135790"],"URL":"https:\/\/doi.org\/10.3390\/ijms27135790","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}